Gordon Smith

Principal Scientist at NexaBiome

Gordon Smith is an experienced Principal Scientist at Fixed Phage since November 2011, focusing on the research and development of novel Bacteriophage immobilisation technology, alongside managing quality systems, experimental design, project management, grant applications, and client communications. Previously, Gordon served as a Research Assistant at the University of Glasgow from April 2008 to October 2011, working on a project that evaluated a dental handpiece cleaner's efficacy, as well as conducting a PhD project on the biofouling of dental handpieces, employing various advanced analytical techniques. Gordon holds a Master’s degree in Molecular Biology from the University of Strathclyde and a Bachelor of Science (Hons) in Microbiology from the University of Glasgow.

Location

Glasgow, United Kingdom

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices


NexaBiome

NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.


Employees

11-50

Links